🚀 VC round data is live in beta, check it out!
Akebia Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Akebia Therapeutics and similar public comparables like Benitec Biopharma, Neumora Therapeutics, Recbio, Climb Bio and more.
Akebia Therapeutics Overview
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Founded
2007
HQ
Employees
181
Website
Sectors
Financials (LTM)
EV
$246M
Akebia Therapeutics Financials
Akebia Therapeutics reported last 12-month revenue of $235M.
In the same LTM period, Akebia Therapeutics generated $197M in gross profit and had net loss of ($9M).
Revenue (LTM)
Akebia Therapeutics P&L
In the most recent fiscal year, Akebia Therapeutics reported revenue of $236M and EBITDA of $22M.
Akebia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $235M | XXX | $236M | XXX | XXX | XXX |
| Gross Profit | $197M | XXX | $197M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | — | XXX | $22M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (4%) | XXX | (2%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Akebia Therapeutics Stock Performance
Akebia Therapeutics has current market cap of $379M, and enterprise value of $246M.
Market Cap Evolution
Akebia Therapeutics' stock price is $1.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $246M | $379M | -1.0% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAkebia Therapeutics Valuation Multiples
Akebia Therapeutics trades at 1.0x EV/Revenue multiple, and 11.3x EV/EBITDA.
EV / Revenue (LTM)
Akebia Therapeutics Financial Valuation Multiples
As of April 10, 2026, Akebia Therapeutics has market cap of $379M and EV of $246M.
Equity research analysts estimate Akebia Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akebia Therapeutics has a P/E ratio of (44.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $379M | XXX | $379M | XXX | XXX | XXX |
| EV (current) | $246M | XXX | $246M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 10.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| P/E | (44.5x) | XXX | (70.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Akebia Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Akebia Therapeutics Margins & Growth Rates
Akebia Therapeutics' revenue in the last 12 month declined by (6%).
Akebia Therapeutics' revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $1.0M for the same period.
Akebia Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (6%) | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (258%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 27% | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Akebia Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Neumora Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Cuorips | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akebia Therapeutics M&A Activity
Akebia Therapeutics acquired XXX companies to date.
Last acquisition by Akebia Therapeutics was on XXXXXXXX, XXXXX. Akebia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Akebia Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAkebia Therapeutics Investment Activity
Akebia Therapeutics invested in XXX companies to date.
Akebia Therapeutics made its latest investment on XXXXXXXX, XXXXX. Akebia Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Akebia Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Akebia Therapeutics
| When was Akebia Therapeutics founded? | Akebia Therapeutics was founded in 2007. |
| Where is Akebia Therapeutics headquartered? | Akebia Therapeutics is headquartered in United States. |
| How many employees does Akebia Therapeutics have? | As of today, Akebia Therapeutics has over 181 employees. |
| Who is the CEO of Akebia Therapeutics? | Akebia Therapeutics' CEO is John P. Butler. |
| Is Akebia Therapeutics publicly listed? | Yes, Akebia Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Akebia Therapeutics? | Akebia Therapeutics trades under AKBA ticker. |
| When did Akebia Therapeutics go public? | Akebia Therapeutics went public in 2014. |
| Who are competitors of Akebia Therapeutics? | Akebia Therapeutics main competitors are Benitec Biopharma, Neumora Therapeutics, Recbio, Climb Bio. |
| What is the current market cap of Akebia Therapeutics? | Akebia Therapeutics' current market cap is $379M. |
| What is the current revenue of Akebia Therapeutics? | Akebia Therapeutics' last 12 months revenue is $235M. |
| What is the current revenue growth of Akebia Therapeutics? | Akebia Therapeutics revenue growth (NTM/LTM) is (6%). |
| What is the current EV/Revenue multiple of Akebia Therapeutics? | Current revenue multiple of Akebia Therapeutics is 1.0x. |
| Is Akebia Therapeutics profitable? | No, Akebia Therapeutics is not profitable. |
| What is the current net income of Akebia Therapeutics? | Akebia Therapeutics' last 12 months net income is ($9M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.